Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2020

01-12-2020 | Peritoneal Cancer | ASO Author Reflections

ASO Author Reflections: Targeting the Immunosuppressive Tumor Microenvironment for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

Author: Carlos H. F. Chan, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Login to get access

Excerpt

Peritoneal carcinomatosis (PC) is a common and deadly metastatic spread from gastrointestinal and pancreaticobiliary cancers. In 2020, over 333,000 new cancer cases from the digestive system were estimated in the United States.1 Between 2009 and 2015, metastatic disease was present in 18% of hepatobiliary, 21% of colorectal, and 52% of pancreatic cancer patients at the time of diagnosis.1 Five-year survival of patients with metastatic disease remains poor with 2% in hepatobiliary cancers, 3% in pancreatic cancers and 14% in colorectal cancers.1 While some patients can undergo aggressive surgery and systemic therapy, many are not candidates for any treatment and only have a few weeks to live. …
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–34.CrossRef
2.
Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12:54.CrossRef
3.
Lemke-Miltner CD, Blackwell SE, Yin C, et al. Antibody opsonization of a TLR9-agonist-containing virus-like particle enhances in situ immunization. J Immunol. 2020;204:1386–94.CrossRef
4.
5.
Milhem M, Gonzales R, Medina T, et al. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res. 2018;78(13 Suppl):Abstract nr CT144.
Metadata
Title
ASO Author Reflections: Targeting the Immunosuppressive Tumor Microenvironment for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer
Author
Carlos H. F. Chan, MD, PhD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08640-1

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

Breast Oncology

Letter to Editor: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Miscalculation of Sensitivity and False-Negative Rate

ASO Author Reflections

ASO Author Reflection: Axillary Dissection for Negative Lymph Nodes in Inflammatory Breast Cancer—Need for Clinical Trials to Reassess Standard of Care

ASO Author Reflections

ASO Author Reflections: The De-Escalation of Sentinel Node Biopsy for Breast Cancer

ASO Author Reflections

ASO Author Reflections: Why the Surgeon, Who is the Person Most Influential in the Management of Breast Cancer, Must Have a Multidisciplinary Mindset

ASO Author Reflections

ASO Author Reflections: Use of Peritoneal Cancer Index (PCI) to Evaluate Carcinomatosis in Ovarian Cancer

Health Services Research and Global Oncology

Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future